Vergelijking van de effecten van Smart App-ondersteund superslow joggen en stationair fietsen op de respiratoire functie en aerobe fitheid bij studenten
Vergelijking van de effecten van Smart App-ondersteund Super-Langzaam Joggen en Stationair Fietsen op de ademhalingsfunctie en aerobe fitheid bij studenten
As health awareness continues to rise, more people are prioritizing exercise to improve physical condition and enhance overall fitness. For those lacking exercise habits, selecting a simple, accessible, and effective workout becomes crucial. Against a backdrop of prolonged sitting and inactivity, "super slow jogging" is gaining attention. This aerobic exercise involves a slow walking pace and low intensity, yet burns more calories than regular walking, making it an ideal entry-level activity for beginners or those with lower fitness levels. This study aims to investigate whether incorporating super slow jogging training can effectively enhance cardiorespiratory fitness and respiratory function, comparing its outcomes with other exercise types. The purpose of this experiment is academic research, primarily exploring the impact of exercise intervention on physiological functions. It is not intended for health screening or medical diagnosis.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Daliao
-
Kaohsiung City, Daliao, Taiwan, 831301
- No. 151, Jinxue Rd.
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- required no regular exercise training in the past six months
- ability to safely perform high-intensity cycling exercise
Exclusion Criteria:
- musculoskeletal limitations that prevented cycling exercise
- recent infection
- known cardiopulmonary disease or medical history affecting cardiovascular or respiratory function
- smoking
- use of medications that may influence cardiopulmonary responses to exercise
- other contraindications to exercise testing according to the American College of Sports Medicine (ACSM) guidelines
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Super slow jogging
A smart app will provide pacing assistance, adjusting step frequency weekly: Week 1: 150 steps per minute Week 2: 180 steps per minute Week 3: 190 steps per minute Week 4: 200 steps per minute |
This study is a randomized controlled trial employing simple randomization, where participants draw lots to assign groups. The experiment comprises three groups: the super-slow jogging group, the stationary bicycle group, and the control group. Both exercise intervention groups underwent 50-minute training sessions comprising a 10-minute warm-up, 30-minute main exercise, and 10-minute cool-down. Super-Slow Jogging Group: Utilized a smart app for pacing assistance, adjusting step frequency weekly: Week 1: 150 steps/minute Week 2: 180 steps/minute Week 3: 190 steps/minute Week 4: 200 steps/minute Stationary Cycling Group: Participants will engage in continuous cycling training at moderate intensity (60% VO₂max). Control Group: No exercise training intervention. |
|
Experimenteel: moderate exercise training
Continuous cycling training at moderate intensity of 60% VO₂max |
This study is a randomized controlled trial employing simple randomization, where participants draw lots to assign groups. The experiment comprises three groups: the super-slow jogging group, the stationary bicycle group, and the control group. Both exercise intervention groups underwent 50-minute training sessions comprising a 10-minute warm-up, 30-minute main exercise, and 10-minute cool-down. Super-Slow Jogging Group: Utilized a smart app for pacing assistance, adjusting step frequency weekly: Week 1: 150 steps/minute Week 2: 180 steps/minute Week 3: 190 steps/minute Week 4: 200 steps/minute Stationary Cycling Group: Participants will engage in continuous cycling training at moderate intensity (60% VO₂max). Control Group: No exercise training intervention. |
|
Placebo-vergelijker: Control
not perform any exercise training |
This study is a randomized controlled trial employing simple randomization, where participants draw lots to assign groups. The experiment comprises three groups: the super-slow jogging group, the stationary bicycle group, and the control group. Both exercise intervention groups underwent 50-minute training sessions comprising a 10-minute warm-up, 30-minute main exercise, and 10-minute cool-down. Super-Slow Jogging Group: Utilized a smart app for pacing assistance, adjusting step frequency weekly: Week 1: 150 steps/minute Week 2: 180 steps/minute Week 3: 190 steps/minute Week 4: 200 steps/minute Stationary Cycling Group: Participants will engage in continuous cycling training at moderate intensity (60% VO₂max). Control Group: No exercise training intervention. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Cardiopulmonary Fitness
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
VO2max (ml/kg/mL) |
Before intervention and the end of intervention at 12 weeks
|
|
Baseline anthropometric of the participants
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
Age (yr) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
VEmax (L/min) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
AT% (%VO₂max) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
Resting O₂ pulse (mL·beat-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
Max O₂ pulse (mL·beat-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
MIP (cmH2O) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
MEP (cmH2O) |
Before intervention and the end of intervention at 12 weeks
|
|
Baseline anthropometric of the participants
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
Height (cm) |
Before intervention and the end of intervention at 12 weeks
|
|
Baseline anthropometric of the participants
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
Weight (kg) |
Before intervention and the end of intervention at 12 weeks
|
|
Baseline anthropometric of the participants
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
BMI (kg/m²) |
Before intervention and the end of intervention at 12 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Lung function
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
FEV1 (L) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
FVC (L) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
FEV₁/FVC (%) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
FEF25-75% (L·s-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
PEF (L·min-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
MVV (L·min-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
Breathing reserve (%) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Tijdsspanne: Before intervention and the end of intervention at 12 weeks
|
Dynamic Index (DI%) |
Before intervention and the end of intervention at 12 weeks
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- 114-0561
- 114-2813-C-242-003-B (Ander subsidie-/financieringsnummer: National Science and Technology Council, Taiwan)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .